Factors in predicting initial in-office therapeutic dosages of alprostadil for the treatment of organic impotence.
The use of intracavernous penile injections of alprostadil for treating organic impotence is well-established. Using blood pressure measurements, especially systolic BP and MABP as measured in a flat supine position, the dosage of alprostadil required to achieve satisfactory erections in men with organic impotence can be predicted. This guidance can significantly influence the outcome of therapy by reducing the number of titrated diagnostic injections and the time required for the patient to achieve satisfactory results.